AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 364393
Drug: Furosemide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (2 mg/kg intravenously)
Trial: 28616772
Drug: Smoke_less (CBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoke_less (CBT program: four weekly group sessions and two telephone calls over 5 weeks, n = 51)
Trial: 27899150
Drug: Trials reporting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trials reporting treatment effect estimate and/or p-value
Trial: 27899150
Drug: Trials with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trials with no treatment effect estimate or p-value posted
Trial: 20729619
Drug: Add on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add on LAM to ADV monotherapy (Group 3)
Trial: 20729619
Drug: Switch to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to ADV monotherapy (Group 1)
Trial: 17039651
Drug: Zostavax vaccine
RxNorm normalized name: ZOSTAVAX VACCINE INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zostavax vaccine
Trial: 10476589
Drug: abciximab (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: abciximab (bolus and 12 hour infusion) with weight-adjusted low-dose heparin
Trial: 10476589
Drug: Weight-adjusted heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-adjusted heparin alone
Trial: 8758450
Drug: Clonidine treatment
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine treatment (10 days program)
Trial: 1951162
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation (WHO recommended dose)
Trial: 6112411
Drug: Intra-articular orgotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular orgotein (4 mg/week for 6 weeks)
Trial: 6112411
Drug: Intra-articular aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular aspirin (4 mg/week for 6 weeks)
Trial: 24134405
Drug: Single subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous 1500 U/kg rEPO at day-1
Trial: 18416955
Drug: Adjunct research
RxNorm normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunct research project (Tromsø Mammography and Breast Cancer study)
Trial: 18416955
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm (no adjunct research project)
Trial: 1670591
Drug: Dideoxyinosine (ddl)
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dideoxyinosine (ddl) administered orally in three divided doses totaling 60, 120, 180, 360, or 540 mg per square meter of body-surface area per day for 24 weeks
Trial: 1670591
Drug: Dideoxyinosine (ddl)
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dideoxyinosine (ddl) administered orally
Trial: 26153128
Drug: atrasentan 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atrasentan 0.75 mg/d
Trial: 26153128
Drug: atrasentan 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atrasentan 1.25 mg/d
Trial: 24612248
Drug: Lycopene-enriched virgin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycopene-enriched virgin olive oil (300 ppm) (1.5 mL three times a day)
Trial: 24612248
Drug: Placebo (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1.5 mL three times a day)
Trial: 20380653
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg qd
Trial: 15643227
Drug: Darifenacin controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darifenacin controlled release (3.75 mg once daily)
Trial: 15643227
Drug: Darifenacin controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darifenacin controlled release (7.5 mg once daily)
Trial: 15643227
Drug: Darifenacin controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darifenacin controlled release (15 mg once daily)
Trial: 15643227
Drug: Darifenacin immediate-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darifenacin immediate-release (5 mg 3 times daily)
Trial: 10594399
Drug: OAM b.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAM b.d. (omeprazole 20 mg b.d., amoxycillin 1000 mg b.d., metronidazole 800 mg b.d.)
Trial: 10594399
Drug: OAM t.d.s.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAM t.d.s. (omeprazole 40 mg o.d., amoxycillin 500 mg t.d.s., metronidazole 400 mg t.d.s.)
Trial: 8214416
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg of thyrotropin-releasing hormone (TRH) IV
Trial: 3116661
Drug: Fat (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat (200 ml vegetable oil)
Trial: 3116661
Drug: Control (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (200 ml glucose)
Trial: 22642607
Drug: Red laser
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red laser therapy (660 nm) applied at three points directly on the episiotomy after suturing in a single session between 6-56 hours postpartum.
Trial: 22642607
Drug: Infrared laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infrared laser therapy (780 nm) applied at three points directly on the episiotomy after suturing in a single session between 6-56 hours postpartum.
Trial: 16009884
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a (44-microg three times weekly)
Trial: 16009884
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a (22-microg three times weekly)
Trial: 1872023
Drug: Vaccine A
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine A (adsorbed tetanus toxoid, 69 IIU/0.5 ml)
Trial: 1872023
Drug: Vaccine B
RxNorm normalized name: meningococcal vaccine B and C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine B (adsorbed tetanus toxoid, 212 IIU/0.5 ml)
Trial: 31701429
Drug: EGCG mouthwash
RxNorm normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG mouthwash (starting at 440 μmol/L, three times a day, maximum tolerated dose 2200 μmol/L)
Trial: 27770628
Drug: Intravenous Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous Dexamethasone 30 mg perioperatively
Trial: 25109511
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (tianeptine sodium 12.5 mg)
Trial: 25109511
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (Stablon®)
Trial: 22806076
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (0.3 g/kg)
Trial: 22806076
Drug: Placebo (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.2 g/kg cornstarch maltodextrin + 0.1 g/kg sucrose)
Trial: 7862853
Drug: Caffeine 200
RxNorm normalized name: caffeine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 200 mg at the beginning and 50 mg maintenance dose half-way through the session
Trial: 2144705
Drug: Nicorandil 10
RxNorm normalized name: nicorandil 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil 10 mg twice daily for 3 weeks, then 20 mg twice daily for 3 weeks
Trial: 2144705
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg once daily for 3 weeks, then 100 mg once daily for 3 weeks
Trial: 380608
Drug: Atropine (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (2.0 mg oral, 1.0 mg i.m.)
Trial: 380608
Drug: Hyoscine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine (1.0 mg oral, 0.25-0.5 mg i.m.)
Trial: 380608
Drug: Glycopyrronium (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium (0.2 mg i.m.)
Trial: 31045427
Drug: Interviewer-administered condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interviewer-administered condition (phone or in-person)
Trial: 31045427
Drug: Self-administered condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered condition (via the Assessment Center website)
Trial: 25645169
Drug: iCBT (internet-delivered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iCBT (internet-delivered cognitive behavior therapy)
Trial: 19458926
Drug: Eperisone 300
RxNorm normalized name: acetaminophen / phenyltoloxamine citrate Oral Tablet [Perisine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eperisone 300 mg/day
Trial: 15366324
Drug: Ephedrine (0.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (0.25, 0.5, and 1 mg x kg(‐1))
Trial: 11336107
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (2 g, intravenous)
Trial: 2898319
Drug: Controlled-release naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release naproxen (750 mg or 1000 mg once-a-day)
Trial: 2898319
Drug: Standard marketed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard marketed naproxen (375 mg or 500 mg twice-a-day)
Trial: 2898319
Drug: Controlled-release naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release naproxen (750 mg or 1000 mg once-a-day) during open-label phase
Trial: 25636011
Drug: HalfLytely© 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HalfLytely© 1 L × 2 doses and bisacodyl 5 mg delayed release tablets × 2 tablets (Protocol 1)
Trial: 25636011
Drug: MiraLAX® 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MiraLAX® 5 tablespoons × 2 doses and bisacodyl 5 mg tablets × 2 tablets (Protocol 2)
Trial: 25636011
Drug: MoviPrep 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MoviPrep 1 L × 2 doses (Protocol 3)
Trial: 23486859
Drug: HPV‐16/18 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV‐16/18 vaccine
Trial: 21244304
Drug: Various dystonia
RxNorm normalized name: Alstonia constricta bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various dystonia medications (anticholinergic agents, baclofen, clonazepam, tetrabenazine, clozapine)
Trial: 7681050
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose rate brachytherapy (750 cGy at 10 mm depth for three fractions)
Trial: 27189687
Drug: Better Nights/Better
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Better Nights/Better Days intervention (five-session manual and weekly telephone coach support)
Trial: 25590463
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) with a focus on cognitive restructuring
Trial: 25590463
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) focusing on Stress Management
Trial: 20096466
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (pharmacotherapy and adjunctive psychosocial treatment based on a cognitive‐behavioral model)
Trial: 20096466
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (standard drug treatment)
Trial: 16263860
Drug: Psychotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy treatment over 12 to 16 weeks
Trial: 12411067
Drug: Iodized salt
RxNorm normalized name: calcium iodized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodized salt with an iodine concentration of 25 mg/kg (Group A)
Trial: 12411067
Drug: Iodized salt
RxNorm normalized name: calcium iodized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodized salt purchased from the market + iodized oil capsules containing 400 mg iodine (Group C)
Trial: 1982830
Drug: Subcutaneous (s.c.)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (s.c.) self‐administered R‐EPO (starting dose 92 +/‐ 35 U/kg/week) two times a week
Trial: 1982830
Drug: Intraperitoneal (i.p.)
RxNorm normalized name: Intraperitoneal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal (i.p.) R‐EPO (170 +/‐ 42 U/kg/week) thrice weekly
Trial: 45587
Drug: Floctafenine 200
RxNorm normalized name: floctafenine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Floctafenine 200 mg
Trial: 343967
Drug: Oral meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral meperidine 75 mg
Trial: 343967
Drug: Oral propoxyphene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propoxyphene 65 mg
Trial: 30732471
Drug: Adjunctive anti-radiation
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive anti-radiation shield under the angiographic table (group 2)
Trial: 27317032
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (100 mg rectally)
Trial: 27317032
Drug: Ceftazidime (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (1 g intravenously)
Trial: 25611308
Drug: Cis‐UCA excretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cis‐UCA excretion in urine
Trial: 21088862
Drug: Cold Water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold Water Immersion Therapy (CWIT) (5°C of temperature [SD ±1°])
Trial: 11783762
Drug: Bic/Lac (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bic/Lac (25 mmol/L bicarbonate/15 mmol/L lactate)
Trial: 11783762
Drug: Lac (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lac (35 mmol/L lactate)
Trial: 7962377
Drug: recFSH with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recFSH with buserelin intranasal spray (4 x 150 micrograms per day) in a short protocol (group II)
Trial: 7962377
Drug: recFSH with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recFSH with triptorelin (3.75 mg i.m. in a long protocol) (group IV)
Trial: 7962377
Drug: recFSH with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recFSH with triptorelin (200 micrograms daily s.c. injections) (group V)
Trial: 29286560
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy and motivation-based intervention (n=33)
Trial: 28043418
Drug: Pralidoxime (PAM)
DrugBank: Pralidoxime (DB00733)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pralidoxime (PAM) treatment guided by APACHE II scores and BuChE activity
Trial: 18805335
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment modified based on measurements of fraction of exhaled NO
Trial: 18805335
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment based on NAEPP guidelines (Control)
Trial: 11346806
Drug: Succimer (lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succimer (lead chelator), administered orally in up to three 26-day courses
Trial: 30120478
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination pill (20 mg telmisartan, 2.5 mg amlodipine, 12.5 mg chlorthalidone)
Trial: 30120478
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination pill
Trial: 29231403
Drug: Acupuncture based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture based on meridian differentiation, with main acupoints including Neiguan (PC 6), Shuigou (GV 26), Sanyinjiao (SP 6), Fengchi (GB 20), Lianquan (CV 23), Jialianquan (Extra), Jinjin (EX-HN 12), Yuye (EX-HN 13), retained for 30 min, once daily, 5 treatments a week for 6 weeks.
Trial: 29231403
Drug: Conventional medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medication and rehabilitation training with control acupuncture points selected 5 cm lateral to the main acupoints, retained for 30 min, once daily, 5 treatments a week for 6 weeks.
Trial: 10943584
Drug: Cloricromene (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cloricromene (100 mg orally b.i.d.) for 6 months
Trial: 30357610
Drug: Azithromycin eyedrops
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin eyedrops (2.5 mL/25 mg)
Trial: 30273332
Drug: Inactivated whole
RxNorm normalized name: Inactivated whole Vibrio cholerae Ag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated whole cell pneumococcal vaccine
Trial: 25012429
Drug: Escitalopram 10mg
RxNorm normalized name: Escitalopram 10mg Oral tablet
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram 10mg daily for 12 weeks
Trial: 21603867
Drug: THERACURMIN 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THERACURMIN 150 mg
Trial: 21603867
Drug: THERACURMIN 210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THERACURMIN 210 mg
Trial: 1362888
Drug: Yohimbine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (4 mg three times daily for 3 weeks)
Trial: 6147077
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (beta-blockers and diuretics)
Trial: 6147077
Drug: Low diuretic
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low diuretic doses
Trial: 21304091
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary intervention (PCI) plus optimal medical therapy (OMT)
Trial: 19289623
Drug: Gefitinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib (250 mg/d) plus best supportive care (BSC)
Trial: 19289623
Drug: Gefitinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib (250 mg/d) plus best supportive care (BSC) in EGFR FISH-positive patients
Trial: 11168029
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral azithromycin, 500 mg (n = 362)
Trial: 11168029
Drug: 1.2 MU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 MU benzathine penicillin G, intramuscularly once (n = 374)
Trial: 1454357
Drug: VPB and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VPB and X‐ray treatment
Trial: 1454357
Drug: Second line
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second line combined treatment modalities
Trial: 6201211
Drug: Consolidation regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation regimen A: continuous infusion of 5-azacytidine, 150 mg/sq m/day for 5 days
Trial: 6201211
Drug: Consolidation regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation regimen B: 5-azacytidine plus beta-deoxythioguanosine, 300 mg/sq m/day for 5 days
Trial: 6201211
Drug: Consolidation regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation regimen C: cytosine arabinoside, 100 mg/sq m/day intravenously, thioguanine, 100 mg/sq m orally every 12 hr, plus daunorubicin, 10 mg/sq m every 24 hr daily for 5 days
Trial: 6201211
Drug: Maintenance regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance regimen D: chemotherapy, 5-day infusion of cytosine arabinoside and 2 days of daunorubicin (same doses as induction) given every 13 wk for 1 yr
Trial: 6201211
Drug: Maintenance regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance regimen E: BCG given twice weekly for 1 mo and then monthly for 1 yr
Trial: 6201211
Drug: Maintenance regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance regimen F: combination of regimens D and E
Trial: 6201211
Drug: Immunotherapy (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (not specified)
Trial: 27590460
Drug: Dexmedetomidine (0.2‐1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.2‐1.5 μg/kg/h)
Trial: 22148972
Drug: Intrathecal combination
RxNorm normalized name: Intrathecal Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal combination of cisplatin and OK‐432 with hyperthermotherapy (Group A)
Trial: 22148972
Drug: Intrathecal combination
RxNorm normalized name: Intrathecal Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal combination of cisplatin and OK‐432 without hyperthermotherapy (Group B)
Trial: 18235115
Drug: Imatinib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (600 mg/d) in mild liver dysfunction group
Trial: 18235115
Drug: Imatinib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (300 mg/d) in moderate and severe liver dysfunction groups
Trial: 18235115
Drug: Imatinib (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (various doses) across all liver dysfunction groups